Acrotech Biopharma Inc. is a specialty pharmaceutical company founded in 2018. Acrotech’s mission is to build a global platform to develop and commercialize innovative and proprietary medications focusing in oncology and dermatology.

Acrotech entered the oncology space in March 2019 by acquiring a portfolio of FDA-approved hematology/oncology drugs and a complete commercial and medical infrastructure. Today Acrotech markets 5 injectable oncology brands in the USA and is a leader in Peripheral T-Cell Lymphoma. Acrotech’s drugs are administered in the clinical setting by the healthcare providers. The company works very closely with the health care community to make its brands accessible to the patient population that needs them.

Outside the US, Acrotech brands are marketed through various global partners. Acrotech has partnerships covering major markets like EU, Canada, Japan, China, and Latin America. Acrotech continues to expand its portfolio in oncology and dermatology through creative licensing and internal R&D programs.

In the near term, Acrotech is also preparing to commercialize, in the USA, a biosimilar pipeline in the immuno-oncology space through its sister company CuraTeq.